Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer (vit D & PCa)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00953225|
Recruitment Status : Completed
First Posted : August 6, 2009
Results First Posted : April 6, 2015
Last Update Posted : October 9, 2017
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: vitamin D3 Drug: Placebo daily for one year||Phase 2|
Vitamin D promotes the differentiation of prostate cancer (PCa) cells, maintains the differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising the possibility that vitamin D deficiency over time promotes the progression of subclinical PCa to clinical disease. These considerations support the use of vitamin D3 as a chemopreventive agent.
We hypothesize that a daily dose of vitamin D3 (4,000 IU) taken for one year by Veterans diagnosed with low-risk, early-stage PCa, who are eligible for active surveillance will: a) result in a measurable decrease of serum PSA levels in a significant number of enrolled subjects, and b) be associated with a stabilization or improvement of their PCa pathology, as assessed through histological examination of prostate tissue biopsy specimens (Gleason score and percent of positive biopsies) obtained at the end of the study, as part of their standard medical care for active surveillance.
This VA Merit application proposes to conduct a randomized, placebo-controlled clinical study aimed at measuring the efficacy of vitamin D3 (4000IU/day) supplementation in Veterans diagnosed with early-stage prostate cancer, who elect to have their disease monitored through active surveillance (before considering definitive therapy). The main objectives of this proposed clinical study are as follows:
- To determine whether a daily supplement of 4,000 IU of vitamin D3 taken for twelve months will result in a measurable and significant decrease of serum PSA levels in Veterans diagnosed with low-risk, early stage PCa (Gleason score 6, PSA 10, clinical stage T1C or T2a), who elect to have their disease monitored through active surveillance for at least one year.
- To determine in enrolled Veterans the pathology status of their PCa by analyzing prostate tissue biopsy specimens at the end of the study (Gleason score and percentage of positive biopsies), and by comparing them with those obtained before enrollment in this study, as part of their standard medical care.
The implementation of these proposed studies will allow us to assess whether vitamin D3 supplementation can be utilized as a chemopreventive regimen in Veterans diagnosed with low-risk, early stage PCa, and provide a useful addition to active surveillance.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||83 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer|
|Actual Study Start Date :||January 7, 2010|
|Actual Primary Completion Date :||December 15, 2013|
|Actual Study Completion Date :||October 30, 2014|
Experimental: Vitamin D3
4,000 IU vitamin D3 daily for one year
Drug: vitamin D3
4,000 IU daily for one year
Placebo Comparator: Placebo
Placebo daily for one year
Drug: Placebo daily for one year
- PSA Slope (Trajectory) or the Change in PSA Level Over Time [ Time Frame: 1 year (visits # 1-8) ]Change in PSA (ng/mL) from baseline to 1 year visit, which include the baseline through 1 year follow-up.
- Number of Positive Biopsy Cores (Out of Twelve) Compared to the Corresponding Values Assessed Before Enrollment [ Time Frame: 1 year ]Change in the number of positive cores per subject from the pre-study prostate biopsy to the repeat prostate biopsy following study participation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00953225
|United States, South Carolina|
|Ralph H. Johnson VA Medical Center, Charleston, SC|
|Charleston, South Carolina, United States, 29401-5799|
|Medical University of South Carolina|
|Charleston, South Carolina, United States, 29425|
|Principal Investigator:||Sebastiano Gattoni-Celli, MD||Ralph H. Johnson VA Medical Center, Charleston, SC|